ArticleNature2021
Hippo signalling maintains ER expression and ER
Abstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Interactions between circular RNAs (circRNAs) and the Hippo pathway in cancer.Molecular biology reports · 2026Review
- Ultrasound-responsive nanodroplets activate the Hippo pathway via ROS-MST1-YAP cascade for breast cancer therapy.Ultrasonics sonochemistry · 2026Article
- Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer.Nature communications · 2026Article
- Targeting YAP: mechanistic breakthroughs and therapeutic prospects in reversing organ fibrosis.Molecular and cellular biochemistry · 2026Review
- Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.Breast cancer research : BCR · 2026Article
- Estrogen promotes osteogenesis via YAP1-driven activation of ERα orchestrated through TEAD1 binding to the ERα promoter.Journal of molecular histology · 2026Article
- Targeting NPSR1-mediated Hippo-YAP1 dysregulation suppresses gastric cancer progression.Cellular and molecular life sciences : CMLS · 2026Article
- GPSAdb 2.0: an expanded atlas of gene-perturbation transcriptomes with enhanced tools for regulatory gene discovery.Nucleic acids research · 2026Article
- Galectin-3 promotes FBXL5-dependent ubiquitination and degradation of YAP1 to constrain colorectal cancer growth.Frontiers in immunology · 2026Article
- Integrin αvβ3 as a Non-Genomic Estrogen Receptor in Breast Cancer for Signaling Pathways and Crosstalk.Cells · 2025Review
- The role of TEAD4 gene in the Hippo signaling pathway in triple-negative breast cancer and targeted therapy strategies.BMC medical genomics · 2025Article
- Crosstalk between YAP/TAZ and ERα in mechanical and hormonal signaling in the skeletal system.Acta biochimica et biophysica Sinica · 2025Review
- KYNA Ameliorates Hepatic Ischemia-Reperfusion Injury by Activating the Hippo Signalling Pathway via FTO-Dependent m6A Demethylation of LATS1.Cell proliferation · 2025Article
- The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2.The Journal of biological chemistry · 2025Article
- Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein.Breast cancer research : BCR · 2025Article
- Review
- WISP1 inhibition of YAP phosphorylation drives breast cancer growth and chemoresistance via TEAD4 activation.Anti-cancer drugs · 2025Article
- Decoding gene expression profiles of Hippo signaling pathway components in breast cancer.Molecular biology reports · 2025Article
- Atypical Hippo signaling network: uncovering novel insights into head and neck cancer biology and advancements in precision intervention.Frontiers in cell and developmental biology · 2025Review
- Cell signaling inFrontiers in cellular and infection microbiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Shenghong MaDepartment of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Zhengming WuDepartment of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Feng YangHoward Hughes Medical Institute, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Jianmin ZhangDepartment of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY, USA.ORCID http://orcid.org/0000-0001-7844-6254
Randy L JohnsonDepartment of Cancer Biology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Michael G RosenfeldHoward Hughes Medical Institute, Department of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1572-156X
Kun-Liang GuanDepartment of Pharmacology, University of California San Diego, La Jolla, CA, USA. kuguan@ucsd.edu.ORCID http://orcid.org/0000-0003-1892-0174
Funding
The mTOR and Hippo pathway in cell growth and cancerR35CA196878 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUAN, KUN-LIANG · 2015 to 2019
$4.0MMolecular Mechanism and Therapy for Ocular MelanomaR01CA217642 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER · 2017 to 2022
$2.4MThe role of TAZ in breast cancer initiation and progressionR01CA207504 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ZHANG, JIANMIN · 2017 to 2021
$2.0MNCI NIH HHS R01 CA207504NCI NIH HHS R01 CA217642NCI NIH HHS R35 CA196878NIH HHS GM51586
Abstract
PubMed holds no abstract for this paper.
Indexed as
Signal TransductionAdaptor Proteins, Signal TransducingAmphiregulinAnimalsBreast NeoplasmsCell DifferentiationCell LineageCells, CulturedEstrogen Receptor alphaFemaleHippo Signaling PathwayHumansMCF-7 CellsMiceProteasome Endopeptidase ComplexProtein Serine-Threonine KinasesAdaptor Proteins, Signal TransducingAmphiregulinDCAF1 protein, humanESR1 protein, humanEstrogen Receptor alphaLATS1 protein, humanLATS2 protein, humanProteasome Endopeptidase ComplexProtein Serine-Threonine KinasesTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsTumor Suppressor ProteinsUbiquitinUbiquitin-Protein LigasesWWTR1 protein, humanYAP1 protein, humanYAP-Signaling Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.